Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Munich EUR

Madrigal Pharmaceuticals Inc (YDO1.MU)

Compare

328.70

+5.20

+(1.61%)

At close: 5:26:15 PM GMT+1

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL)

GlobeNewswire 8 hours ago

MDGL
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the M

GlobeNewswire 9 days ago

MDGL
Exploring Three High Growth Tech Stocks in the United States

The United States market has shown robust performance with a 2.4% increase over the last week and a remarkable 25% rise over the past year, while earnings are projected to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong revenue growth potential and innovative capabilities to capitalize on these favorable market conditions.

Simply Wall St. 29 days ago

MDGL

FIVN

TUYA
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (NASDAQ: MDGL) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence. Madrigal unveiled those figures Monday morning.

Motley Fool last month

MDGL
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales

Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.

Zacks last month

MDGL
Why Madrigal Pharmaceuticals Stock Is Sinking Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. Madrigal reported preliminary Q4 net sales for its metabolic steatohepatitis (MASH) drug Rezdiffra of between $100 million and $103 million. Madrigal also stated that it should end 2024 with cash, cash equivalents, restricted cash, and marketable securities of around $931 million.

Motley Fool last month

MDGL
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectivelyPreliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 millionAs of year-end 2024, more than 11,800 patients on RezdiffraMadrigal to present at the 43rd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. PST (5:15 p.m. EST) on Wednesday January 15, 2025 CONSHOHOCKEN, Pa.,

GlobeNewswire last month

MDGL
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations Site, Events and Presentations. About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering no

GlobeNewswire last month

MDGL
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook

Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. 2 months ago

MDGL
Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $427 from $415 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Published first on

TipRanks 2 months ago

MDGL
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (NASDAQ: MDGL). When it was approved in March 2024, Rezdiffra became the only medicine approved by the Food and Drug Administration (FDA) to treat metabolic-associated steatohepatitis (MASH), a disease that's characterized by fatty deposits on the liver, toughening and stiffening of liver tissue (fibrosis), and eventually scarring of the liver (cirrhosis). Since then, Madrigal has been focused on getting more patients on treatment so that it can generate sales.

Motley Fool 2 months ago

MDGL
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks 2 months ago

MDGL
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against the other biotech stocks. Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth Biotechnology stocks are among the most volatile in the market […]

Insider Monkey 2 months ago

MDGL
The first MASH drug could open the door for others — including GLP-1s

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

Pharma Voice 3 months ago

IVA.PA

MDGL
John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC

Insights into the Investment Shifts of a Hedge Fund Titan

GuruFocus.com 3 months ago

MDGL

AU
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Zacks 3 months ago

^GSPC

MDGL

TBPH
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

There's a bright future ahead for this company.

Motley Fool 3 months ago

MDGL
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

Zacks 3 months ago

CORT

TBPH

^GSPC
3 High Growth Tech Stocks Leading The US Market

The United States market has shown robust performance, rising 2.3% over the last week and 35% over the past year, with earnings forecasted to grow by 15% annually. In this thriving environment, a good stock often combines strong growth potential with innovative technology solutions that align well with current market trends and future growth expectations.

Simply Wall St. 3 months ago

FICO

MDGL

ADMA
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday, November 13, 2024 at 2:00 P.M. ESTThe presentation will be webcast live and may be accessed here. 7th Annual Evercore HealthCONx ConferenceWednesday, December 4, 2024 at 9:35 A.M. EST Piper Sandler 36th Annual Healthcare ConferenceThursday, Dece

GlobeNewswire 3 months ago

MDGL

Performance Overview

Return	YDO1.MU	S&P 500
YTD	+11.46%	+2.24%
1-Year	+57.12%	+20.70%
3-Year	+335.36%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Madrigal Pharmaceuticals Inc (YDO1.MU)

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Exploring Three High Growth Tech Stocks in the United States

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales

Why Madrigal Pharmaceuticals Stock Is Sinking Today

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook

Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?

The first MASH drug could open the door for others — including GLP-1s

John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

3 High Growth Tech Stocks Leading The US Market

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Performance Overview